Search

everythinglearnresearchcommunity

for

Search:↓

Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Cyproterone acetate and ethinylestradiol effectively reduce hirsutism and acne in women.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Baricitinib is effective for severe alopecia areata but has some side effects.

Apremilast did not work for treating severe alopecia areata.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.